These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 22692843

  • 1. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Adami S, Rossini M.
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M.
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [Abstract] [Full Text] [Related]

  • 3. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [Abstract] [Full Text] [Related]

  • 4. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D, Viapiana O, Idolazzi L, Fracassi E, Ionescu C, Dartizio C, Troplini S, Kunnathully V, Adami S, Rossini M.
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [Abstract] [Full Text] [Related]

  • 5. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 6. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

  • 7. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan 23; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 8. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, Gatti D.
    Calcif Tissue Int; 2013 Apr 23; 92(4):324-9. PubMed ID: 23430197
    [Abstract] [Full Text] [Related]

  • 9. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.
    J Clin Endocrinol Metab; 2011 Apr 23; 96(4):972-80. PubMed ID: 21289258
    [Abstract] [Full Text] [Related]

  • 10. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR.
    J Bone Miner Res; 2011 Mar 23; 26(3):530-7. PubMed ID: 20839290
    [Abstract] [Full Text] [Related]

  • 11. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group.
    J Bone Miner Res; 2007 Dec 23; 22(12):1832-41. PubMed ID: 17708711
    [Abstract] [Full Text] [Related]

  • 12. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May 23; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
    Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL.
    J Bone Miner Res; 2015 Feb 23; 30(2):216-24. PubMed ID: 25196993
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.
    J Clin Endocrinol Metab; 2008 Jun 23; 93(6):2149-57. PubMed ID: 18381571
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
    Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S.
    J Clin Endocrinol Metab; 2011 May 23; 96(5):1555-9. PubMed ID: 21367927
    [Abstract] [Full Text] [Related]

  • 18. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Osteoporos Int; 2015 Oct 23; 26(10):2521-7. PubMed ID: 25990355
    [Abstract] [Full Text] [Related]

  • 19. Denosumab update.
    Lewiecki EM.
    Curr Opin Rheumatol; 2009 Jul 23; 21(4):369-73. PubMed ID: 19424068
    [Abstract] [Full Text] [Related]

  • 20. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 23; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.